|
JP2003531588A
(ja)
|
2000-04-11 |
2003-10-28 |
ジェネンテック・インコーポレーテッド |
多価抗体とその用途
|
|
KR100983997B1
(ko)
|
2001-01-09 |
2010-09-28 |
메르크 파텐트 게엠베하 |
수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법
|
|
AU2003251597A1
(en)
|
2002-06-19 |
2004-01-06 |
Abgenix, Inc. |
Method for predicting response to epidermal growth factor receptor-directed therapy
|
|
WO2004032961A1
(en)
|
2002-10-10 |
2004-04-22 |
Merck Patent Gmbh |
Bispecific anti-erb-b antibodies and their use in tumor therapy
|
|
WO2004046386A1
(en)
|
2002-11-15 |
2004-06-03 |
Genomic Health, Inc. |
Gene expression profiling of egfr positive cancer
|
|
WO2004094613A2
(en)
|
2003-04-22 |
2004-11-04 |
Ibc Pharmaceuticals |
Polyvalent protein complex
|
|
ATE485307T1
(de)
|
2003-11-07 |
2010-11-15 |
Ablynx Nv |
Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
|
|
LT3173073T
(lt)
|
2004-05-03 |
2025-01-10 |
Ipsen Biopharm Ltd. |
Liposomos, skirtos vaistų pristatymui
|
|
US7498142B2
(en)
|
2006-01-31 |
2009-03-03 |
Yeda Research And Development Co., Ltd. |
Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
|
|
EP2089543B1
(en)
|
2006-11-15 |
2020-07-01 |
BioFire Diagnostics, LLC |
High density self-contained biological analysis
|
|
TW200846362A
(en)
|
2007-02-09 |
2008-12-01 |
Symphogen As |
A polyclonal antibody product
|
|
BRPI0808551B1
(pt)
|
2007-03-01 |
2022-04-05 |
Symphogen A/S |
Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
|
|
WO2009030239A1
(en)
|
2007-09-06 |
2009-03-12 |
Genmab A/S |
Novel methods and antibodies for treating cancer
|
|
EP3124497B1
(en)
|
2007-09-14 |
2020-04-15 |
Adimab, LLC |
Rationally designed, synthetic antibody libraries and uses therefor
|
|
US8159931B2
(en)
|
2007-12-11 |
2012-04-17 |
Broadcom Corporation |
Orthogonal pilot code construction
|
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
|
NZ589143A
(en)
|
2008-05-14 |
2012-02-24 |
Genomic Health Inc |
Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
|
|
WO2010019952A2
(en)
|
2008-08-15 |
2010-02-18 |
Merrimack Pharmaceuticals, Inc. |
Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response
|
|
RU2012148398A
(ru)
|
2010-04-18 |
2014-05-27 |
Иеда Рисеч Энд Девелопмент Ко. Лтд. |
МОЛЕКУЛЫ И СПОСОБЫ ПРИМЕНЕНИЯ МОЛЕКУЛ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНЕЙ, АССОЦИИРОВАННЫХ С ErbB/ErbB ЛИГАНДАМИ
|
|
EP2566512A1
(en)
|
2010-05-04 |
2013-03-13 |
Merrimack Pharmaceuticals, Inc. |
Antibodies against epidermal growth factor receptor (egfr) and uses thereof
|
|
WO2011140151A1
(en)
|
2010-05-04 |
2011-11-10 |
Dyax Corp. |
Antibodies against epidermal growth factor receptor (egfr)
|
|
MX2013010444A
(es)
|
2011-03-15 |
2014-03-21 |
Merrimack Pharmaceuticals Inc |
Superar la resistencia a inhibidores de la via erbb.
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
EP2554551A1
(en)
|
2011-08-03 |
2013-02-06 |
Fundacio Institut mar d'Investigacions Médiques (IMIM) |
Mutations in the epidermal growth factor receptor gene
|
|
WO2013138371A1
(en)
|
2012-03-12 |
2013-09-19 |
Merrimack Pharmaceuticals, Inc. |
Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
|
|
AU2013202947B2
(en)
|
2012-06-13 |
2016-06-02 |
Ipsen Biopharm Ltd. |
Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
|
|
MA39599A
(fr)
|
2014-05-14 |
2016-10-05 |
Merrimack Pharmaceuticals Inc |
Dosage et administration d'agents thérapeutiques anti-egfr
|
|
CA2983890A1
(en)
|
2015-04-24 |
2016-10-27 |
Merrimack Pharmaceuticals, Inc. |
Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies
|